Effect of adding selegiline to levodopa in early, mild Parkinson's disease

BMJ

Volumn 317, Issue 7172, 1998, Pages 1586-

  Counsell, Carl ^a   Aaltonen, Helena ^b   Kilkku, Olavi ^b   Heinonen, Esa ^b  

^a AUSTIN HEALTH   (Australia)

^b ORION CORPORATION   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; LEVODOPA; SELEGILINE;

CLINICAL TRIAL; DRUG COMBINATION; FOLLOW UP; HUMAN; META ANALYSIS; NOTE; PARKINSON DISEASE;

ANTIPARKINSON AGENTS; CLINICAL TRIALS; DRUG COMBINATIONS; FOLLOW-UP STUDIES; HUMANS; LEVODOPA; PARKINSON DISEASE; SELEGILINE;

EID: 0032488209     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.317.7172.1586     Document Type: Letter

References (12)

1. Ben-Schlomo Y, Churchyard A, Head J, Hurwitz B, Overstall P, Ockelford J, et al. Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry. BMJ 1998; 316: 1191–1196 (18 April.).
2. Mäki-Ikola O, Kilkku O, Heinonen E. Effect of adding selegiline to levodopa in early, mild Parkinson's disease. BMJ 1996; 312: 702.
3. Parkinson's Study Group. Mortality in DATATOP. A multi-center trial in early Parkinson's disease. Ann Neurol 1998; 43: 318–325.
4. Myllylä VV, Sotaruemi KA, Hakulinen P, Mäki-Ikola O, Heinonen EH. Selegiline as the primary treatment of Parkinson's disease—a long-term double-blind study. Acta Neurol Scand 1997; 95: 211–218.
5. Larsen JP, Boas J, Norwegian-Danish Study Group. The effects of early selegiline therapy on long-term levodopa treatment and Parkinsonian disability: an interim analysis of a Norwegian-Danish 5-year study. Movement Disorders 1997; 12: 175–182.
6. Olanow C, Myllylä V, Sotaniemi K, Larsen J-P, Pålhagen S, Przuntek H, et al. Effect of selegiline on mortality in patients with Parkinson's disease: A meta-analysis. Neurology 1998; 51: 825–830.
7. Ben-Schlomo Y, Churchyard A, Head J, Hurwitz B, Overstall P, Ockelford J, et al. Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry. BMJ 1998; 316: 1191–1196 (18 April.).
8. Olanow C, Myllylä V, Sotaniemi K, Larsen J-P, Pålhagen S, Przuntek H, et al. Effect of selegiline on mortality in patients with Parkinson's disease: A meta-analysis. Neurology 1998; 51: 825–830.
9. Caraceni TA. Dopamine agonists and deprenyl in comparison to levodopa for initial treatment in patients with Parkinson's disease [abstract]. Mov Disord 1997; 12: 81.
10. Di Rocco A, Culliton D, Yahr M. Comparative mortality and longevity in parkinsonian patients with L-dopa and selegiline [abstract]. Mov Disord 1996; 11: 708.
11. Parkinson's Study Group. Mortality in DATATOP. A multi-center trial in early Parkinson's disease. Ann Neurol 1998; 43: 318–325.
12. Birkmayer W, Knoll J, Riederer P, Youdim M, Hars V, Marton J. Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: A longterm study. J Neural Transm 1985; 64: 113–127.